Prognostic significance of XRCC4 expression in hepatocellular carcinoma.
Prognostic significance of XRCC4 expression in hepatocellular carcinoma.
复制标题
XRCC4表达在肝细胞癌中的预后意义
DOI：
10.18632/oncotarget.21360
复制
发表时间：
2017-10-20
期刊：
影响因子：
--
通讯作者：
Long XD
中科院分区：
文献类型：
--
作者：
Lu J;Wang XZ;Zhang TQ;Huang XY;Yao JG;Wang C;Wei ZH;Ma Y;Wu XM;Luo CY;Xia Q;Long XD
背景我们前期的研究表明，X射线修复互补4（XRCC4）的变异可能参与肝细胞癌（肝癌）的肿瘤发生。本研究旨在探讨XRCC4表达对肝癌患者可能的预后意义以及对经动脉化疗栓塞（TACE）治疗选择的可能价值。材料与方法我们进行了基于医院的回顾性分析（包括421例肝癌病例），以分析XRCC4对肝癌预后和TACE的影响。使用免疫组织化学测试 XRCC4 表达水平。使用半数最大抑制浓度（IC50）评估癌细胞对抗癌药物阿霉素的敏感性。结果 XRCC4表达与肿瘤分期、肝硬化、微血管密度等病理特征显着相关。 XRCC4表达是肝癌的独立预后因素，TACE治疗对XRCC4高表达肝癌患者的预后无影响。更有趣的是，TACE 改善了 XRCC4 低表达的肝癌患者的预后。从功能上来说，XRCC4 过度表达增加，而 XRCC4 敲除降低了癌细胞对阿霉素的 IC50。结论 XRCC4可能是肝癌患者的独立预后因素，降低XRCC4表达可能有利于肝癌术后辅助TACE治疗。
Background Our previous investigations have shown that the variants of X-ray repair complementing 4 (XRCC4) may be involved in hepatocellular carcinoma (hepatocarcinoma) tumorigenesis. This study aimed to investigate the possible prognostic significance of XRCC4 expression for hepatocarcinoma patients and possible value for the selection of transarterial chemoembolization (TACE) treatment. Materials and Methods We conducted a hospital-based retrospective analysis (including 421 hepatocarcinoma cases) to analyze the effects of XRCC4 on hepatocarcinoma prognosis and TACE. The levels of XRCC4 expression were tested using immunohistochemistry. The sensitivity of cancer cells to anti-cancer drug doxorubicin was evaluated using the half-maximal inhibitory concentration (IC50). Results XRCC4 expression was significantly correlated with pathological features including tumor stage, liver cirrhosis, and micro-vessel density. XRCC4 expression was an independent prognostic factor of hepatocarcinoma, and TACE treatments had no effects on prognosis of hepatocarcinoma patients with high XRCC4 expression. More intriguingly, TACE improved the prognosis of hepatocarcinoma patients with low XRCC4 expression. Functionally, XRCC4 overexpression increased while XRCC4 knockdown reduced the IC50 of cancer cells to doxorubicin. Conclusions These results suggest that XRCC4 may be an independent prognostic factor for hepatocarcinoma patients, and that decreasing XRCC4 expression may be beneficial for post-operative adjuvant TACE treatment in hepatocarcinoma.
登录
查看更多内容
影响因子：
5.6
作者：
Ma X;Li RS;Wang J;Huang YQ;Li PY;Wang J;Su HB;Wang RL;Zhang YM;Liu HH;Zhang CE;Ma ZJ;Wang JB;Zhao YL;Xiao XH
通讯作者：
Xiao XH
XRCC4 的隐性变异使中国女性易患非 BRCA1/2 乳腺癌，并通过核定位失调损害 DNA 损伤反应
影响因子：
--
作者：
He M;Hu X;Chen L;Cao AY;Yu KD;Shi TY;Kuang XY;Shi WB;Ling H;Li S;Qiao F;Yao L;Wei Q;Di GH;Shao ZM
通讯作者：
Shao ZM
MicroRNA-24 调节黄曲霉毒素 B1 相关的肝细胞癌预后和肿瘤发生
影响因子：
--
作者：
Liu YX;Long XD;Xi ZF;Ma Y;Huang XY;Yao JG;Wang C;Xing TY;Xia Q
通讯作者：
Xia Q
影响因子：
3.8
作者：
Huang, Xiao-Ying;Yao, Jin-Guang;Long, Xi-Dai
通讯作者：
Long, Xi-Dai
影响因子：
5
作者：
Divella R;Daniele A;Abbate I;Savino E;Casamassima P;Sciortino G;Simone G;Gadaleta-Caldarola G;Fazio V;Gadaleta CD;Sabbà C;Mazzocca A
通讯作者：
Mazzocca A